Download PDF
Semin Thromb Hemost 2002; 28(1): 5-18
DOI: 10.1055/s-2002-20560
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Malignancy by Activation of the Plasminogen System

Leo R. Zacharski1 , Deborah L. Ornstein2 , Esteban C. Gabazza3 , Corina N. D'Alessandro-Gabazza3 , Antonio Brugarolas4 , Jeffrey Schneider5
  • 1VA Medical and Regional Office Center, White River Junction, Vermont and Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire
  • 2Division of Hematology/Oncology, Wilford Hall Medical Center, Lackland Air Force Base, Texas
  • 3Third Department of Internal Medicine, Mie University School of Medicine, 514 Edobashi 2-chome 174, Tsu-city, Mie Prefecture, Japan
  • 4Department of Oncology, Faculty of Medicine, University of Navarra, Pamplona, Spain
  • 5222 Station Plaza North, Mineola, New York
Further Information

Publication History

Publication Date:
05 March 2002 (online)

    Permissions and Reprints

ABSTRACT

The blood coagulation mechanism in general and the plasminogen system in particular contribute to malignant growth and dissemination in complex ways. This article reviews the extensive literature that has accumulated over the past half-century on effects of plasminogen activation on the natural history of experimental animal and human malignancy. Although the potent enzymes generated upon plasminogen activation may have a direct effect on tumor cells, it is more likely that their mechanism of action is related to disruption of the tumor cell-extracellular matrix interaction. These observations suggest novel approaches to the experimental therapy of cancer.

KEYWORD

Malignancy - fibrinolysis - plasminogen activation - extracellular matrix

REFERENCES

  • 1 Collen D. The plasminogen (fibrinolytic) system.  Thromb Haemost. 1999;  82 259-270
    PubMedGoogle Scholar
  • 2 Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-uPAR-PAI-1 system.  Thromb Haemost . 1999;  82 298-304
    PubMedGoogle Scholar
  • 3 Kwaan H C. Modulation of tumor matrix by components of the plasminogen-plasmin system. In: Adany R, ed. Tumor Matrix Biology Boca Raton, FL: CRC Press 1995: 215-234
    Google Scholar
  • 4 Dunbar S D, Ornstein D L, Zacharski L R. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.  Exp Opin Invest Drugs . 2000;  9 2085-2092
    CrossrefPubMedGoogle Scholar
  • 5 Cliffton E E, Grossi C E. Effect of human plasmin on the toxic effects and growth of blood-borne metastasis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit.  Cancer . 1956;  9 1147-1152
    PubMedGoogle Scholar
  • 6 Laki K, Yancey S T. Fibrinogen and the tumor problem. In: Laki K, ed. Fibrinogen New York: Marcel Dekker 1968: 359-367
    Google Scholar
  • 7 Hoover Jr C H, Ketcham A S. Techniques for inhibiting tumor metastases.  Cancer . 1975;  35 5-14
    PubMedGoogle Scholar
  • 8 Klener P, Bubenik J, Donner L. Influence of heparin and defibrinase on transplantability of syngeneic tumors in mice.  Neoplasma . 1978;  25 631-635
    PubMedGoogle Scholar
  • 9 Grossi C E, Agostino D, Cliffton E E. The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma.  Cancer Res . 1960;  20 605-608
    PubMedGoogle Scholar
  • 10 Fisher B, Fisher E R. Host factors influencing the development of metastases.  Surg Clin North Am . 1962;  42 335-351
    PubMedGoogle Scholar
  • 11 Agostino D, Cliffton E E. Anticoagulants and the development of pulmonary metastases.  Arch Surg . 1961;  84 449-453
    PubMedGoogle Scholar
  • 12 Cliffton E E, Agostino D. Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism.  Cancer . 1962;  15 276-283
    PubMedGoogle Scholar
  • 13 Agostino D, Cliffton E E. Trauma as a cause of localization of blood-borne metastases: preventative effect of heparin and fibrinolysin.  Ann Surg . 1965;  161 97-102
    PubMedGoogle Scholar
  • 14 Hilgard P, Hiemeyer V. The cytotoxic effect of plasmin on Yoshida sarcoma cells.  Rev Fr Etudes Clin Biol . 1969;  14 902-904
    PubMedGoogle Scholar
  • 15 Agostino D, Cliffton E E. Decrease in pulmonary metastases: potentiation of nitrogen mustard effect by heparin and fibrinolysin.  Ann Surg . 1963;  157 400-408
    PubMedGoogle Scholar
  • 16 Fisher B, Fisher E R. Experimental studies of factors which influence hepatic metastases. VII. Effect of anticoagulants.  Surgery . 1961;  50 240-247
    PubMedGoogle Scholar
  • 17 Agostino D, Cliffton E E. Decrease of metastases of carcinosarcoma Walker 256 with irradiation and heparin or fibrinolytic agents.  Radiology . 1962;  79 848-854
    PubMedGoogle Scholar
  • 18 Cliffton E E, Agostino D. Irradiation and anticoagulant therapy to prevent pulmonary metastases of the V2 carcinoma in rabbits.  Radiology . 1963;  80 236-243
    PubMedGoogle Scholar
  • 19 Cliffton E E. Effect of fibrinolysis on spread of cancer.  Fed Proc . 1966;  25 89-93
    PubMedGoogle Scholar
  • 20 Kudrjashov B A, Kalishevskaya T M, Kolomina S M. Blood anticoagulating system and malignant tumours.  Nature . 1969;  222 548-550
    PubMedGoogle Scholar
  • 21 Wood Jr S, Holyoke D, Yardley J H. Mechanisms of metastasis production by blood-borne cancer cells.  Can Cancer Conf . 1961;  4 167-223
    PubMedGoogle Scholar
  • 22 Wood Jr S. Mechanisms of establishment of tumor metastases. In: Ioachim HL, ed. Pathobiology Annual New York: Appleton-Century-Crofts 1971: 281-308
    Google Scholar
  • 23 Wood Jr S. Experimental studies of the intravascular dissemination of ascitic V2 carcinoma cells in the rabbit, with special reference to fibrinogen and fibrinolytic agents.  Bull Schweiz Akad Med Wiss . 1964;  20 92-121
    PubMedGoogle Scholar
  • 24 Taniguchi T. Basic and clinical studies on chemotherapy of cancer.  J Jpn Cancer Soc . 1972;  7 290-309
    PubMedGoogle Scholar
  • 25 Fisher B, Fisher E R. Anticoagulants and tumor cell lodgment.  Cancer Res . 1967;  27 421-425
    PubMedGoogle Scholar
  • 26 Grossi C E, Agostino D, Melamed M, Cliffton E E. The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood.  Cancer . 1961;  14 957-962
    PubMedGoogle Scholar
  • 27 Thornes R D. Fibrinogen and the interstitial behavior of cancer. In: Ioachim HL, ed. Pathobiology Annual New York: Appleton-Century-Crofts 1971: 281-308
    Google Scholar
  • 28 Thornes R D, Martin W T. The cytopathic effect of fibrinolytic agents and human placental fractions on HELA cells.  Ir J Med Sci . 1961;  431 487-494
    PubMedGoogle Scholar
  • 29 Tanaka K, Kohga S, Kinjo M, Kodama Y. Tumor metastasis and thrombosis, with special reference to thromboplastic and fibrinolytic activities of tumor cells.  Monograph on Cancer Research. New York: GANN 1977: 97-119
    Google Scholar
  • 30 Murthy M S, Summaria L J, Miller R J. Inhibition of tumor implantation at sites of trauma by plasminogen activators.  Cancer . 1991;  68 1724-1730
    PubMedGoogle Scholar
  • 31 Lisnell A, Mellgren J. Effect of heparin, protamine, dicoumarol, streptokinase and epsilon-amino-n-caproic acid on the growth of human cells in vitro.  Acta Pathol . 1963;  57 145-153
    PubMedGoogle Scholar
  • 32 Purushotham A D, Brown D C, McCulloch P, Choy A, George W D. Streptokinase inhibits pulmonary tumor seeding in an animal experimental model.  J Surg Oncol . 1994;  57 3-7
    PubMedGoogle Scholar
  • 33 Yamamoto M, Yamada T, Fukunaga K. Potentiation of cytotoxic drug effects. The significance of the combined therapy of cytotoxic drug and urokinase.  Cancer Clin (Gan To Rinshou) . 1971;  17 750-759
    PubMedGoogle Scholar
  • 34 Yamamoto M, Nashima A, Nagamatsu S. Potentiation of cytotoxic drug effects. The significance of the combined therapy with dextran sulfate.  Recent Med (Saishin Igaku) . 1973;  28 996-1009
    PubMedGoogle Scholar
  • 35 Taya T. Enhanced cell killing by thio-TEPA and urokinase.  J Jpn Soc Urol (Nihon Hinnyouki Gakkai Zasshi) . 1979;  70 15-27
    PubMedGoogle Scholar
  • 36 Nagai N. Coagulation and fibrinolysis system in tumor of the bladder. Effect of fibrinolytic and antifibrinolytic agents on N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced rat bladder tumor.  J Jpn Soc Urol (Nihon Hinnyouki Gakkai Zasshi) . 1985;  76 31-40
    PubMedGoogle Scholar
  • 37 Miyoshi T, Saito M, Arimizu N. Effect of radiation therapy combined with fibrinolytic agents on Ehrlich solid tumor in mice.  J Jpn Soc Radiol . 1982;  42 895-898
    PubMedGoogle Scholar
  • 38 Peterson H-I. Experimental studies on fibrinolysis in growth and spread of tumour.  Acta Chir Scand . 1968;  Suppl 394-394 Abst
    PubMedGoogle Scholar
  • 39 Peterson H-I, Appelgren K L, Rudenstam C-M, Lewis D H. Studies on the circulation of experimental tumours.  Eur J Cancer . 1969;  5 91-97
    PubMedGoogle Scholar
  • 40 Peterson H-I, Appelgren K L, Rosengren B HO. Fibrinogen metabolism in experimental tumours.  Eur J Cancer . 1969;  5 535-542
    PubMedGoogle Scholar
  • 41 Rudenstam C M. Effect of fibrinolytic and antifibrinolytic therapy on the dissemination of experimental tumours.  Bibl Anat . 1967;  9 418-424
    PubMedGoogle Scholar
  • 42 Sugimura M, Tsubakimoto M, Kashibayashi Y, Kawakatsu K. Effect of human serum plus streptokinase on spontaneous pulmonary metastases of Vx2 carcinomas transplanted in the maxillary sinus of the rabbit.  Int J Oral Surg . 1975;  4 112-120
    PubMedGoogle Scholar
  • 43 Kodama Y, Tanaka K. Effect of urokinase on growth and metastases of rabbit V2 carcinoma.  Gann . 1978;  69 9-18
    PubMedGoogle Scholar
  • 44 DeWys W D, Kwaan H C, Bathina S. Effect of defibrination on tumor growth and response to chemotherapy.  Cancer Res . 1976;  36 3584-3587
    PubMedGoogle Scholar
  • 45 Chikahisa L, Matsuo K, Yamada Y. Modulation of tumor cell motility by plasmin.  Invasion Metastasis . 1997;  17 323-333
    PubMedGoogle Scholar
  • 46 Roszkowski W, Stachurska J, Gerdin B, Saldeen T, Kopec M. Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 sarcoma in BALB/c mice.  Eur J Cancer Clin Oncol . 1981;  17 889-892
    PubMedGoogle Scholar
  • 47 Hilgard P, Thornes R D. Anticoagulants in the treatment of cancer.  Eur J Cancer . 1976;  12 755-762
    PubMedGoogle Scholar
  • 48 Suzuki M, Abe I, Sato H. Combination of chemotherapy and proteolytic enzymes (an experimental approach).  Recent Med (Saishin No Igaku) . 1973;  28 920-925
    PubMedGoogle Scholar
  • 49 Zacharski L R, Rickles F R. Warfarin in the treatment of cancer. In: Poller L, Hirsh J, eds. Oral Anticoagulants London: Edward Arnold 1996: 228-238
    Google Scholar
  • 50 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism.  N Engl J Med . 2000;  342 1953-1958
    CrossrefPubMedGoogle Scholar
  • 51 Zacharski L R, Ornstein D L. Heparin and cancer.  Thromb Haemost . 1998;  80 10-23
    PubMedGoogle Scholar
  • 52 Cliffton E E, Grossi C E. The rationale of anticoagulants in the treatment of cancer.  J Med . 1974;  5 107-113
    PubMedGoogle Scholar
  • 53 Zacharski L R. Anticoagulation in the treatment of cancer in man. In: Donati M, Davidson JF, Garattini S, eds. Malignancy and the Hemostatic System New York: Raven Press 1981: 113-128
    Google Scholar
  • 54 Thornes R D. Anticoagulant therapy in patients with cancer.  J Ir Med Assoc . 1969;  62 426-429
    PubMedGoogle Scholar
  • 55 Larsen V, Mogensen B, Amris C J, Storm O. Fibrinolytic enzyme in the treatment of patients with cancer.  Dan Med Bull . 1964;  2 137-140
    PubMedGoogle Scholar
  • 56 Holt J AG. The extranuclear control of mitosis and cell function. A theory of cellular organization.  Med Hypotheses . 1980;  6 145-192
    PubMedGoogle Scholar
  • 57 Daido R, Koike A, Nomiyama S, Nakamura M, Watanabe T. The effect of selective administration of anticancer agents in massive doses combined with fibrinolytic enzyme (urokinase) in a case of hepatic cancer.  Jpn J Cancer Clin (Gan No Rinsho) . 1972;  18 285-289
    PubMedGoogle Scholar
  • 58 Martin Algarra S, Dy C, Anton Aparicio L. Tratamiento del carcinoma pulmonar de celulas pequeñas con urokinasa y quimioterapia intensiva. Resultados preliminares.  Rev Med Univ Navarra . 1986;  30 41-48
    PubMedGoogle Scholar
  • 59 Calvo F A, Harguindey S S, Anton Aparicio L. Urokinase combination chemotherapy for treatment of small cell carcinoma of the lung.  Cancer Treat Symp . 1985;  2 105-108
    PubMedGoogle Scholar
  • 60 Calvo F A, Hidalgo O F, Gonzalez F. Urokinase combination chemotherapy in small cell lung cancer. A phase II study.  Cancer . 1992;  70 2624-2630
    PubMedGoogle Scholar
  • 61 Salsali M, Cliffton E E. Superior vena cava obstruction with carcinoma of the lung.  Surg Gynecol Obstet . 1965;  121 783-788
    PubMedGoogle Scholar
  • 62 Salsali M, Cliffton E E. Superior vena caval obstruction in carcinoma of lung.  NY State J Med . 1969;  69 2875-2880
    PubMedGoogle Scholar
  • 63 Salsali M, Cliffton E E. Superior vena caval obstruction with lung cancer.  Ann Thorac Surg . 1968;  6 437-442
    PubMedGoogle Scholar
  • 64 Clery A P, Hogan B L, Holland P DJ. Early experience in a controlled clinical trial using streptokinase induced fibrinolysis during resections for colon and rectal carcinomas in an attempt to prevent hematogenous metastasis.  J Ir Coll Phys Surg . 1972;  1 91-95
    PubMedGoogle Scholar
  • 65 Thornes R D. Fibrinolytic therapy of leukaemia.  J R Coll Surg Irel . 1970;  6 123-128
    PubMedGoogle Scholar
  • 66 Thornes R D. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants.  Cancer . 1975;  35 91-97
    PubMedGoogle Scholar
  • 67 Thornes R D. Inhibition of antiplasmin, and effect of protease I in patients with leukaemia.  Lancet . 1968;  2 1220-1223
    PubMedGoogle Scholar
  • 68 Thornes R D, Deasy P F, Carroll R, Reen D J, MacDonell J D. The use of the proteolytic enzyme brinase to produce autocytotoxicity in patients with acute leukemia and its possible role in immunotherapy.  Cancer Res . 1972;  32 280-284
    PubMedGoogle Scholar
  • 69 Thornes R D. Unblocking or activation of the cellular immune mechanism by induced proteolysis in patients with cancer.  Lancet . 1974;  2 382-384
    PubMedGoogle Scholar
  • 70 Thornes R D, Smyth H, Browne O. The effects of proteolysis on the human immune mechanism in cancer.  J Med . 1974;  5 92-97
    PubMedGoogle Scholar
  • 71 Thornes R D, Smyth H, Brown O, Holland P DJ. B.C.G. plus protease I in malignant melanoma. (Letter to the Editor).  Lancet . 1973;  2 1386
    PubMedGoogle Scholar
  • 72 O'Brien E T, Thornes R D, O'Brien D, Hogan B. Inhibition of antiplasmin, and fibrinolytic effect of protease in patients with cancer.  Lancet . 1968;  1 173-176
    PubMedGoogle Scholar
  • 73 Hashimoto I, Kodama M, Hironaka T, Tanaka Y, Kubo Y. Basic studies on combined use of anticancer agents and urokinase.  Med Postgrad . 1970;  8 358-362
    PubMedGoogle Scholar
  • 74 Tsue M, Egami T, Murakami M. Clinical use of urokinase combined with mitomycin-C on intraperitoneal perfusion therapy.  Jpn J Clin Exp Med (Rinsho To Kenkyu) . 1972;  49 2259-2260
    PubMedGoogle Scholar
  • 75 Fukumoto K, Tadata M. Two clinical cases with stomach cancer significantly improved by combined use of 5-FU and urokinase.  Med Postgrad . 1972;  10 35-36
    PubMedGoogle Scholar
  • 76 Goto M. A clinical case with juvenile carcinomatous peritonitis improved by combined use of anticancer agent and urokinase.  Med Postgrad . 1970;  8 325-327
    PubMedGoogle Scholar
  • 77 Nakamura R. Clinical effect of combined therapy with mitomycin and urokinase on progressive uterine cancer.  Med Postgrad . 1971;  9 115-118
    PubMedGoogle Scholar
  • 78 Hisazumi H, Uchibayashi T, Naito K, Misaki T, Miyazaki K. The prophylactic use of thio-TEPA and urokinase in transitional cell carcinoma of the bladder: a preliminary report.  J Urol . 1975;  114 394-398
    PubMedGoogle Scholar
  • 79 Ogawa S, Okawa T, Kaneta K, Tsuya A, Utsunomiya J. Experiences gained in the treatment of locally advanced breast cancer with various combined treatment. A clinical trial aimed at improving the effectiveness of cancer chemotherapy.  J Jpn Soc Radiol . 1976;  36 1069-1081
    PubMedGoogle Scholar
  • 80 Yamamoto M, Saito T, Ouchi S. Clinical evaluation of the combination therapy of various anticancer agents and urokinase: comparison of tissue culture urokinase with urinary urokinase.  Jpn J Cancer Chemother (Gan To Kagaku Ryouho) . 1982;  9 1461-1473
    PubMedGoogle Scholar
  • 81 Saijo N. Chemotherapy against pulmonary metastasis from uterine cervical carcinoma.  Jpn J Cancer Chemother (Gan To Kagaku Ryouhou) . 1982;  9 992-997
    PubMedGoogle Scholar
  • 82 Haku S. Clinical use of urokinase on tumor of the bladder and ureteral stone.  Jpn J Clin Exp Med (Rinsho To Kenkyu) . 1972;  49 2631-2632
    PubMedGoogle Scholar
  • 83 Matsui R, Sakamoto H, Yamaguchi K, Masuda M, Noda N. Combined therapy with lysosome labiliser (urokinase MDS) and anticancer agent.  Jpn J Clin Exp Med (Rinsho To Kenkyu) . 1972;  49 2290-2296
    PubMedGoogle Scholar
  • 84 Niitani H, Suzuki A, Chikada C. Combined therapy with lysosome labilizer and anticancer agent.  Recent Med (Saishin Igaku) . 1968;  23 21168-21172
    PubMedGoogle Scholar
  • 85 Nagamatsu S, Nakajima M, Yamamura M. Experimental and clinical studies on combined use with protease as method to potentiate the effect of anticancer agents. A report in the 19th Japan Chemotherapy Society General Meeting, Tokyo, June 10-12, 1971, pp 17-19
    Google Scholar
  • 86 Yamamoto M, Yamada T, Fukunaga S. Method to potentiate the effect of anti-tumor-drugs. Meanings of urokinase combination.  Jpn J Cancer Clin (Gan No Rinsho) . 1971;  17 750-759
    PubMedGoogle Scholar
  • 87 Yamamoto M. The role of induced fibrinolysis in cancer chemotherapy.  Recent Med (Saishin Igaku) . 1971;  26 365-379
    PubMedGoogle Scholar
  • 88 Tsuboi S, Kajiwara T, Kamata T. Combined therapy with urokinase on terminal cancer.  Clin Rep . 1971;  5 478-485
    PubMedGoogle Scholar
  • 89 Tanaka K. Cancer and fibrinolysis.  Jpn J Cancer Chemother (Gan To Kagaku Ryouhou) . 1975;  2 545-557
    PubMedGoogle Scholar
  • 90 Shimoyama M, Niitani H, Kimura K, Taniguchi T, Inagaki J. Lysosome and chemotherapy. Combined therapy of mitomycin C and the lysosome labilizer plasmin.  Jpn J Clin Exp Med (Igaku No Ayumi) . 1968;  65 349-352
    PubMedGoogle Scholar
  • 91 Niitani H. Anticancer therapy and its combination with lysosome labilizer.  Recent Med (Saishin Igaku) . 1973;  28 912-919
    PubMedGoogle Scholar
  • 92 Suda Y, Sekiine T. Biliary and pancreatic excretion of mitomycin C with special reference to the concomitant use of urokinase.  Jpn J Cancer Chemother (Gan To Kagaku Ryouhou) . 1985;  12 2225-2226
    PubMedGoogle Scholar
  • 93 Kato S, Matsuno S, Kakizaki K, Fukaya Y, Akaishi S. Effects of urokinase on the transfer of 1-hexylcarbamoyl-5-fluorouracil (HCFU) into blood, bile and pancreatic juice.  Jpn J Cancer Chemother (Gan To Kagaku Ryouhou) . 1985;  12 2134-2138
    PubMedGoogle Scholar
  • 94 Hanzawa T. Anticancer agents in the treatment of two cases of carcinomatous peritonitis and combined therapy with urokinase. Direct Correspondence 1970: 85-86
    Google Scholar
  • 95 Dahl S. Treatment of cancer patients with infusions of plasmin.  Oncologia . 1996;  20 35-38
    PubMedGoogle Scholar
  • 96 Zacharski L R, Wojtukiewicz M Z, Costantini V, Ornstein D L, Memoli V A. Pathways of coagulation/fibrinolysis activation in malignancy.  Semin Thromb Hemost . 1992;  18 104-116
    PubMedGoogle Scholar
  • 97 Vasudevan J, Humphries J E, Gonias S L. Binding of anisoylated lys-plasminogen streptokinase activator complex to cells in culture.  Thromb Haemost . 1993;  69 370-374
    PubMedGoogle Scholar
  • 98 Hajjar K A, Acharya S S. Annexin II and regulation of cell surface fibrinolysis.  Ann NY Acad Sci . 2000;  902 265-271
    PubMedGoogle Scholar
  • 99 Meehan K R, Zacharski L R, Maurer L H. Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.  Blood Coagul Fibrinolysis . 1995;  6 105-112
    PubMedGoogle Scholar
  • 100 Hatton M WC, Ross B, Bardossy L. The procoagulant state of the VX-2 tumor in rabbit lung in vivo: relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor.  Thromb Haemost . 1999;  82 1694-1702
    PubMedGoogle Scholar
  • 101 Back N, Shields R R, DeWitt G, Branshaw R H, Ambrus C M. Uptake of fibrinogen and fibrinolytic enzymes by neoplastic tissue.  J Natl Cancer Inst . 1966;  36 171-180
    PubMedGoogle Scholar
  • 102 Amris C J, Larsen V, Mogensen B, Storm O. Turnover and distribution of 131I-labeled porcine plasmin in man and dog.  Dan Med Bull . 1964;  2 146-152
    PubMedGoogle Scholar
  • 103 Costantini V, Zacharski L R. Fibrin and cancer.  Thromb Haemost . 1993;  69 406-414
    PubMedGoogle Scholar
  • 104 Kwaan H C. The role of fibrinolysis in disease processes.  Semin Thromb Hemost . 1984;  10 71-79
    PubMedGoogle Scholar
  • 105 Adany R. Tumor Matrix Biology New York: CRC Press 1995
  • 106 Ashbaugh C D, Warren H B, Carey V J, Wessels M R. Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection.  J Clin Invest . 1998;  201 550-560
    PubMedGoogle Scholar
  • 107 Peuhkurinen K J, Risteli L, Melkko J T. Thrombolytic therapy with streptokinase stimulates collagen breakdown.  Circulation . 1970;  83 1969-1975
    PubMedGoogle Scholar
  • 108 Salomon D S. Cell-cell and cell-extracellular matrix adhesion molecules communicate with growth factor receptors: an interactive signaling web.  Cancer Invest . 2000;  18 591-593
    PubMedGoogle Scholar
  • 109 Weiner H L, Zagzag D. Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer.  Cancer Invest . 2000;  18 544-554
    PubMedGoogle Scholar
  • 110 Goldfinger L E, Jiang L, Hopkinson S B, Stack M S, Jones J C. Spatial regulation and activity modulation of plasmin by high-affinity binding to the G domain of the alpha3 subunit of laminin-5.  J Biol Chem . 2000;  275 34887-34893
    CrossrefPubMedGoogle Scholar
  • 111 Felding-Habermann B, Ruggeri Z M, Cheresh D A. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments.  J Biol Chem . 1992;  267 5070-5077
    PubMedGoogle Scholar
  • 112 Pintucci G, Bikfalvi A, Klein S, Rifkin D B. Angiogenesis and the fibrinolytic system.  Semin Thromb Hemost . 1996;  22 517-524
    PubMedGoogle Scholar
  • 113 Sawaya R. Fibrinolysis and the Central Nervous System Philadelphia: Hanley & Belfus 1990
  • 114 Glas-Greenwalt P, ed. Fibrinolysis in Disease. The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities.  New York: CRC Press 1995
    Google Scholar
  • 115 Collen D. Towards improved thrombolytic therapy.  Lancet . 1993;  342 34-36
    CrossrefPubMedGoogle Scholar
  • 116 The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. Prehospital Thrombolysis for Myocardial Infarction-EMIP Group.  N Engl J Med . 1993;  329 383-389
    CrossrefPubMedGoogle Scholar
  • 117 de Boer P J, Baars J W, Roem D. Activation of fibrinolysis and coagulation during interleukin 2 therapy.  Thromb Haemost . 1991;  65 1053-1053 Abst
    PubMedGoogle Scholar
  • 118 Negrier C, Bordet J C, Durbin S. Haemostasis modifications during interleukin 2 therapy in advanced renal cell cancer.  Thromb Haemost . 1991;  65 1055-1055 Abst
    PubMedGoogle Scholar
  • 119 Francis C W, Onundarson P T, Carstensen E L. Enhancement of fibrinolysis in vitro by ultrasound.  J Clin Invest . 1992;  90 2063-2068
    CrossrefPubMedGoogle Scholar
  • 120 Okamoto S. Mode of action of non-enzymatic activators of fibrinolysis: with reference to an anti-tumor agent and to dextran sulfate. In: von Kaulla KN, Davidson JF, eds. Synthetic Fibrinolytic and Thrombolytic Agents Springfield, IL: Charles C Thomas 1975: 118-129
    Google Scholar
  • 121 von Tempelhoff F G, Harenberg J, Niemann F. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial.  Int J Oncol . 2000;  16 815-824
    PubMedGoogle Scholar
      >